Compare OSUR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | MXCT |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 160.0M |
| IPO Year | 1986 | 2021 |
| Metric | OSUR | MXCT |
|---|---|---|
| Price | $2.86 | $0.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $7.50 |
| AVG Volume (30 Days) | 544.7K | ★ 1.1M |
| Earning Date | 02-24-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,703,000.00 | $34,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | $11.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $0.75 |
| 52 Week High | $4.22 | $4.67 |
| Indicator | OSUR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.73 | 18.48 |
| Support Level | $2.65 | $0.75 |
| Resistance Level | $3.01 | $1.28 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 71.08 | 15.74 |
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.